168 related articles for article (PubMed ID: 27277541)
1. Proteasome inhibitor MG132 potentiates TRAIL-induced apoptosis in gallbladder carcinoma GBC-SD cells via DR5-dependent pathway.
Zhu W; Zhan D; Wang L; Ma D; Cheng M; Wang H; Zhao J; Cai Y; Cheng Z
Oncol Rep; 2016 Aug; 36(2):845-52. PubMed ID: 27277541
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
Yoshida T; Shiraishi T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(13):5662-7. PubMed ID: 15994939
[TBL] [Abstract][Full Text] [Related]
4. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
He Q; Huang Y; Sheikh MS
Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
Inoue T; Shiraki K; Fuke H; Yamanaka Y; Miyashita K; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Anticancer Drugs; 2006 Mar; 17(3):261-8. PubMed ID: 16520654
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5.
Lee YJ; Seol JW; Jeong JK; Moon MH; Park SY
Mol Med Rep; 2011; 4(6):1255-9. PubMed ID: 21850375
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis.
Yoshiba S; Iwase M; Kurihara S; Uchida M; Kurihara Y; Watanabe H; Shintani S
Oncol Rep; 2011 Mar; 25(3):645-52. PubMed ID: 21206980
[TBL] [Abstract][Full Text] [Related]
13. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Seol DW
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
[TBL] [Abstract][Full Text] [Related]
14. Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5.
Kim YH; Shin EA; Jung JH; Park JE; Koo J; Koo JI; Shim BS; Kim SH
Eur J Pharmacol; 2019 Mar; 847():91-96. PubMed ID: 30689998
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
Chen JJ; Chou CW; Chang YF; Chen CC
J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
20. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
